Source: Health Times.com
On July 30, the international authoritative medical journal New England Journal of Medicine published a latest research article showing that Nirsevimab, a monoclonal antibody of respiratory syncytial virus (RSV) jointly developed by Sanofi Pasteur and AstraZeneca and has an extended half-life, significantly reduced the number of cases of lower respiratory tract infection caused by RSV during the entire RSV epidemic season.
RSV is an infectious virus that causes respiratory tract infection. It is the primary pathogen of acute lower respiratory tract infection in infants and young children (mainly bronchitis and pneumonia ) and is also the primary factor in hospitalization for lower respiratory tract infection in infants and young children. Globally, 99% of deaths under the age of 5 are in developing countries due to RSV.
Around the world, almost all children have been infected with RSV before the age of 2, and 80% of infants and young children hospitalized due to RSV infection are originally healthy children. According to research estimates, in 2015, more than 33 million new acute lower respiratory tract infections related to RSV were reported worldwide, resulting in about 3.2 million hospitalizations and 59,600 deaths in hospitals for children under 5 years old. About 45% of hospitalizations and hospital deaths caused by acute lower respiratory tract infection caused by respiratory syncytial virus were infants under 6 months old.
Director of the National Clinical Medical Research Center for Respiratory Diseases , and Professor Shen Kunling of Beijing Children's Hospital said, "RSV infection is the primary factor in hospitalization and even death caused by lower respiratory tract infections such as pneumonia or bronchioles, and it seriously endangers the health of children. Some children with severe conditions may also experience symptoms such as apnea and need to be treated with a ventilator in the ICU, which brings great pain to children and families."
study author, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal and Infant and Pediatric Health Program, Joseph, author of the study of the State Medical University of New York, Professor of Pediatrics, Professor of Microbiology and Immunology, Director of the Global Maternal and Infant and Pediatric Health Program, Joseph, author of the study of the State Medical University of New York, Professor of Pediatrics, Professor of Microbiology and Immunology, Director of the Global Maternal and Infant and Pediatric Health Program, Joseph, author of the study of the State Medical University of New York, Professor of Pediatrics, Professor of Microbiology and Immunology, Director of the Global Maternal and Infant and Pediatric Health Program, Joseph, author of the study of the State Medical University of New York, Professor of Pediatrics, Professor of Microbiology and Immunology, Director of the Global Maternal and Infant and Pediatric Health Program, Joseph, author of the study of the State of New York, Professor of Pediatrics, Professor of Microbiology and Immunology, Director of the Global Maternal and Infant and Pediatric Health Program," said Joseph, author of the study of the study of the State of New York, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal and Infant and Pediatric Health Program. Dr. Domachowske said, "Nirsevimab's data is exciting because it only takes one injection throughout the RSV epidemic season to protect babies from infection. This innovative approach has great potential to reduce the number of outpatients, emergency and hospitalizations and significantly reduce the burden on the healthcare system."
China is one of the highest number of people suffering from RSV infection in the world, and together with Pakistan , India, Nigeria , Indonesia , Indonesia , Indonesia , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rtz3, rt
At present, there is no effective drug for preventing and treating RSV-related diseases in the Chinese market. Due to the lack of effective antiviral drugs and vaccines, treatments are still mainly focused on isolating care and relieving symptoms. In addition, there is a lack of large-scale RSV disease surveillance in China, and the RSV diagnosis rate is also relatively low, which all leads to a serious lack of awareness of RSV.
Currently, based on the evaluation of the results of the Phase B clinical trial, Nirsevimab has been recognized as a "breakthrough therapy" by US Food and Drug Administration and has been approved to be selected as the "Prioritative Drug Program" by European Medicines Administration . In Japan, Nirsevimab was also selected by the Japan Medical Research and Development Agency as the "Priority Development Drugs" in the "Drug Selection Research Program to Promote the Development of New Pediatric Drugs".
Professor Shen Kunling said, "At present, there are still great unmet medical needs in the field of RSV prevention and treatment. If Nirsevimab can be finally launched, it will fill a big gap in the field of RSV infection prevention. We hope to launch relevant clinical trials in China as soon as possible and be approved as soon as possible, so that all Chinese infants and young children will benefit."
